Cargando…

Nintedanib in advanced NSCLC: management of adverse events

Nintedanib plus docetaxel is approved in the EU for the treatment of patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma histology after first-line chemotherapy. Nintedanib in combination with docetaxel has a manageable safety profile in adenocarcinoma NSCLC patie...

Descripción completa

Detalles Bibliográficos
Autor principal:	Lemmens, Liesbeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322586/ https://www.ncbi.nlm.nih.gov/pubmed/30643547 http://dx.doi.org/10.2217/lmt.15.33

Ejemplares similares

Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
por: Reck, Martin, et al.
Publicado: (2015)

Focus on Nintedanib in NSCLC and Other Tumors
por: Manzo, Anna, et al.
Publicado: (2016)

Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib
por: Rahaghi, Franck, et al.
Publicado: (2021)

Recent Advances in the Management of Adverse Events Associated with Lorlatinib
por: Liao, Dehua, et al.
Publicado: (2023)

Clinical development of nintedanib for advanced non-small-cell lung cancer
por: Takeda, Masayuki, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
por: Wind, Sven, et al.
Publicado: (2019)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience
por: Rivera-Ortega, Pilar, et al.
Publicado: (2018)

Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies
por: Grande, Enrique, et al.
Publicado: (2013)

Immunotherapeutic Advances for NSCLC
por: Massafra, Marco, et al.
Publicado: (2021)

Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
por: Kato, Motoyasu, et al.
Publicado: (2019)

Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
por: Chen, Jing, et al.
Publicado: (2021)

Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
por: Antoniu, Sabina A
Publicado: (2012)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Profile of nintedanib in the treatment of solid tumors: the evidence to date
por: Awasthi, Niranjan, et al.
Publicado: (2015)

Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge
por: Vaddepally, Raju, et al.
Publicado: (2022)

Bullous pemphigoid associated with nintedanib
por: Hasson, Amelia M., et al.
Publicado: (2019)

Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC
por: Westeel, Virginie, et al.
Publicado: (2023)

Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy
por: Iseli, Thomas, et al.
Publicado: (2020)

Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
por: Rothschild, Sacha I
Publicado: (2014)

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2015)

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases
por: Wollin, Lutz, et al.
Publicado: (2019)

The Interactions of Nintedanib and Oral Anticoagulants—Molecular Mechanisms and Clinical Implications
por: Grześk, Grzegorz, et al.
Publicado: (2020)

Adverse Events of Oncologic Immunotherapy and Their Management
por: Barber, Fedricker Diane
Publicado: (2019)

Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
por: Mahtani, Reshma, et al.
Publicado: (2019)

CAR T-Cell Therapy: Adverse Events and Management
por: Adkins, Sherry
Publicado: (2019)

Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy
por: Chen, Yiqun, et al.
Publicado: (2023)

Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours
por: Bahleda, Rastislav, et al.
Publicado: (2015)

Management of recurrent pleural mesothelioma: Successful rechallenge with nintedanib in combination with chemotherapy
por: Grosso, Federica, et al.
Publicado: (2018)

Progressive Pleural Effusion as an Immune-Related Adverse Event in NSCLC: A Case Report
por: Shen, Chia-I, et al.
Publicado: (2021)

Author Correction: Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
por: Kato, Motoyasu, et al.
Publicado: (2020)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Nintedanib ameliorates animal model of dermatitis
por: Heo, Min-Jeong, et al.
Publicado: (2020)

Nintedanib-Induced Renal Thrombotic Microangiopathy
por: Fujita, Takeshi, et al.
Publicado: (2021)

Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis
por: Nasser, Mouhamad, et al.
Publicado: (2021)

Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
por: Rodríguez-Portal, José Antonio
Publicado: (2017)

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
por: Bonella, Francesco, et al.
Publicado: (2015)

Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
por: Valenzuela, Claudia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_golmodq8kp1huhi6ljk6n0vf78